BS_TMTV769C
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 145.10512483574243
- age_years
- 5.038
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.347
- BILE_ACID_METABOLISM+0.345
- MYOGENESIS+0.239
- ANDROGEN_RESPONSE+0.222
- UV_RESPONSE_DN+0.193
- PANCREAS_BETA_CELLS+0.184
- HEME_METABOLISM+0.155
- ESTROGEN_RESPONSE_EARLY+0.154
- XENOBIOTIC_METABOLISM+0.130
- ESTROGEN_RESPONSE_LATE+0.116
Top 10 suppressed
- MYC_TARGETS_V2-0.627
- E2F_TARGETS-0.559
- MYC_TARGETS_V1-0.555
- DNA_REPAIR-0.537
- G2M_CHECKPOINT-0.522
- UNFOLDED_PROTEIN_RESPONSE-0.435
- ANGIOGENESIS-0.399
- OXIDATIVE_PHOSPHORYLATION-0.393
- WNT_BETA_CATENIN_SIGNALING-0.381
- IL6_JAK_STAT3_SIGNALING-0.307
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_ME3HKN2C | Ganglioglioma | — | 0.947 |
| 2 | BS_SFKZSJN1 | low-grade glioma | — | 0.928 |
| 3 | BS_G9XE3N9T | pilocytic astrocytoma | — | 0.891 |
| 4 | C3L-02958 | — | cohortA1 | 0.873 |
| 5 | BS_3PYESPHA | Ganglioglioma | — | 0.873 |
| 6 | BS_7N0B2CY1 | Ganglioglioma | — | 0.873 |
| 7 | BS_DMZP9G1H | Ganglioglioma | — | 0.872 |
| 8 | BS_258RRGDM | low-grade glioma | — | 0.869 |
| 9 | C3L-03679 | — | cohortA1 | 0.868 |
| 10 | SRR1339387 | GTEX | — | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.347 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.345 | Inavolisib | — uncovered |
| MYOGENESIS | 0.239 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.222 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.193 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.184 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.155 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.154 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.116 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.116 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.096 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.077 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.073 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.035 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.031 | Temsirolimus | — uncovered |